Altimmune Financials - Benzinga

SPY768.73+0.59%QQQ744.40+0.88%BTC/USD84,304.00+0.81%DIA512.57−0.06%GLD381.14−0.46%TLT77.78−0.58%

Altimmune Inc

ALTNASDAQ

Trade with Public

Trade with Public

$2.94

-0.025-0.84%

Last update: Sep 30, 12:00 PM

Overview News Earnings Forecast Events Price TargetsFinancialsSentiment Ownership Compare Options Stock Report

Altimmune Financials

Altimmune (ALT) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Altimmune Q2 EPS $(0.12) Beats $(0.15) Estimate

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.12) per share which beat the analyst consensus estimate of $(0.15) by 20 percent. This is a 55.56 percent increase over losses of $(0.27) per share from the same

Benzinga Newsdesk

PRO
Altimmune Q1 EPS $(0.18) Beats $(0.25) Estimate.

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.18) per share which beat the analyst consensus estimate of $(0.25) by 28 percent. This is a 30.77 percent increase over losses of $(0.26) per share from the same

Benzinga Newsdesk

Earnings Scheduled For May 13, 2026

Benzinga Insights

Altimmune: Q4 Earnings Insights

Benzinga Insights

PRO
Altimmune Q4 EPS $(0.27) Up From $(0.33) YoY, Sales $26.000K Up From $5.000K YoY

Altimmune (NASDAQ:ALT) reported quarterly losses of $(0.27) per share. This is a 18.18 percent increase over losses of $(0.33) per share from the same period last year. The company reported $26.000 thousand in sales

Benzinga Newsdesk

Earnings Scheduled For March 5, 2026

Benzinga Insights